Objective To provide a comprehensive summary (systematic review) of medication
adherence rates by assessment method and medication type for pediatric patients with …

Background Hydroxyurea is the only Food and Drug Administration approved medication for
sickle cell disease (SCD) with short‐and long‐term benefits for both morbidity and mortality …

Background Adolescents and young adults (AYAs) with sickle cell disease (SCD) are a
vulnerable population with high risk of morbidity that could be decreased with effective self …

Background Increasing numbers of interventions are being developed to support self‐
management for children and young people (CYP) with sickle cell disease (SCD), but no …

Background Sickle cell disease (SCD) is an inherited blood disorder causing acute
complications and chronic progressive end organ damage. SCD is associated with …

Introduction Sickle cell disease (SCD) is an inherited hemoglobinopathy that predominantly
affects African Americans in the United States. The disease is associated with complications …

Background Adherence to illness self‐management among youth with sickle cell disease
(SCD) positively impacts health outcomes and decreases overall healthcare costs. Despite …

Hydroxyurea is an efficacious treatment for sickle cell disease (SCD), but adoption is low
among individuals with SCD. The objective of this study was to examine barriers to patients' …

Transition from pediatric to adult care poses challenges for adolescents with sickle cell
disease (SCD). This study explored the transition perspectives of adolescents with SCD …

Background: Hydroxyurea prevents disease complications among patients with sickle cell
disease (SCD). Although its efficacy has been endorsed by the National Health Lung and …